In vitro investigation of inhalation delivery of nebulized liposomes

článek ve sborníku mimo WoS a Scopus

en

Inhalation therapy is a promising way of drug delivery, but the suitable carrier system plays an important role in its effectiveness. The inhalation administration of two nebulized liposomal systems was investigated in this study. The first system contained dipalmitoylfosfatidylcholine (DPPC), polyethylene glycol (PEG) bonded to dipalmitoylphosphoethanolamine (DPPE), and cholesterol (Chol). The second one consisted of DPPC, phosphatidic acid (PA), and Chol. These systems were nebulized by 2 air-jet nebulizers (AJN): Pari LC Sprint, and Pari LC Sprint Star. The stability during nebulization was assessed for both systems and both nebulizers. Aerodynamic Particle Size Distribution (APSD) of nebulized aerosols was measured. According to the results of the stability and APSD (MMADLC_Sprint_Star 7.39 ± 0.24 µm; MMADLC_Sprint 9.79 ± 0.41 µm), the air-jet nebulizer PARI LC Sprint Star and DPPC-PA-Chol liposomal system were selected as the most promising choice among the tested cases. This combination was used for the investigation of the in vitro inhalation drug delivery. For this purpose, realistic replicas of upper airways and trachea were used and the liposomal vesicles were labeled with fluorescent dye to enable the local deposition evaluation. The nebulized system was inhaled into the airways model with a steady flow rate of 20 l/min and a realistic breathing pattern of a normal tidal breathing regime. In the case of inhalation at a fixed flow rate, more than 90 % of the aerosol mass penetrated below the trachea segment. In the case of the realistic breathing pattern, around 70 % of aerosol mass reached the region below the trachea.

Inhalation therapy is a promising way of drug delivery, but the suitable carrier system plays an important role in its effectiveness. The inhalation administration of two nebulized liposomal systems was investigated in this study. The first system contained dipalmitoylfosfatidylcholine (DPPC), polyethylene glycol (PEG) bonded to dipalmitoylphosphoethanolamine (DPPE), and cholesterol (Chol). The second one consisted of DPPC, phosphatidic acid (PA), and Chol. These systems were nebulized by 2 air-jet nebulizers (AJN): Pari LC Sprint, and Pari LC Sprint Star. The stability during nebulization was assessed for both systems and both nebulizers. Aerodynamic Particle Size Distribution (APSD) of nebulized aerosols was measured. According to the results of the stability and APSD (MMADLC_Sprint_Star 7.39 ± 0.24 µm; MMADLC_Sprint 9.79 ± 0.41 µm), the air-jet nebulizer PARI LC Sprint Star and DPPC-PA-Chol liposomal system were selected as the most promising choice among the tested cases. This combination was used for the investigation of the in vitro inhalation drug delivery. For this purpose, realistic replicas of upper airways and trachea were used and the liposomal vesicles were labeled with fluorescent dye to enable the local deposition evaluation. The nebulized system was inhaled into the airways model with a steady flow rate of 20 l/min and a realistic breathing pattern of a normal tidal breathing regime. In the case of inhalation at a fixed flow rate, more than 90 % of the aerosol mass penetrated below the trachea segment. In the case of the realistic breathing pattern, around 70 % of aerosol mass reached the region below the trachea.

deposition, aerosol, liposom, nebulizer

07.12.2022

Edinburgh, Spojené království

4